ECDCRT @Eurosurveillanc: @ECDC_Flu @ECDC_EU @NLZOH_si @ciberinfec @sciencemedia_es What was the #VaccineEffectiveness against severe #COVID19 of a second booster dose of the bivalent #mRNA vaccine, relative to a first booster dose of a monovalent #vaccine among persons ≥60 years?
Rapid communication from 🇮🇹
@istsupsan @s_brusaferro
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.8.2300105#html_fulltext
🐦🔗: https://n.respublicae.eu/ECDC_EU/status/1629055784079224837
Eurosurveillance | Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022
Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4–5) mRNA vaccine 7–90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4–6 months earlier indicated no significant additional protection (10%; 95% CI: −44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.